National Health (Originator Brand) Amendment Determination 2017 (No. 4) (PB 42 of 2017) (Cth)

PB 42 of 2017

National Health (Originator Brand) Amendment Determination 2017 (No. 4)

National Health Act 1953

I, LOUISE CLARKE, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated          30   May 2017

______________________________________

LOUISE CLARKE

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2017 (No. 4).

(2)     This Determination may also be cited as PB 42 of 2017.

1. Commencement

This Determination commences on 1 June 2017.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1 (after table item 88)

insert:

88A	Fluticasone	Flixotide Flixotide Accuhaler Flixotide Junior Flixotide Junior Accuhaler
88B	Fluticasone with Salmeterol	Seretide Accuhaler 100/50 Seretide Accuhaler 250/50 Seretide Accuhaler 500/50 Seretide MDI 50/25 Seretide MDI 125/25 Seretide MDI 250/25

[2]   Schedule 1 (after table item 248)

insert:

248A Zonisamide Zonegran